Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...
Capital Performance Advisors LLP bought a new position in Incyte Co. (NASDAQ:INCY – Free Report) in the third quarter, ...
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...
Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November ...
On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...
Fintel on MSN13d
B of A Securities Upgrades Incyte (INCY)Fintel reports that on October 30, 2024, B of A Securities upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to ...
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...
Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to purchase an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback